At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PPH VanEck Pharmaceutical ETF
Pre-Mkt 11-02 08:56:52 EST
119.33
+2.41
+2.06%
盘前118.61
-0.72-0.60%
08:52 EST
High120.86Low118.97Vol1.28M
Open119.73D1 Closing116.92Amplitude1.62%
Mkt Cap1.10BTradable Cap1.10BTotal Shares9.24M
T/O152.64MT/O Rate13.83%Tradable Shares9.24M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results
Benzinga Earnings  ·  24 minutes ago
These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results
Eli Lilly price target raised to $1,600 from $1,440 at Cantor Fitzgerald
TIPRANKS  ·  40 minutes ago
Eli Lilly price target raised to $1,600 from $1,440 at Cantor Fitzgerald
Merck price target raised to $155 from $145 at Cantor Fitzgerald
TIPRANKS  ·  41 minutes ago
Merck price target raised to $155 from $145 at Cantor Fitzgerald
Street View: AbbVie's Immunology Strength Fuels Long-Term Growth Optimism
Reuters  ·  56 minutes ago
Street View: AbbVie's Immunology Strength Fuels Long-Term Growth Optimism
Merck to Present Phase 3 Data on Once-Weekly HIV Treatment at HIV Glasgow 2026
Reuters  ·  19:46
Merck to Present Phase 3 Data on Once-Weekly HIV Treatment at HIV Glasgow 2026
Cantor Fitzgerald Adjusts Price Target on Merck to $155 From $145
MT Newswires Live  ·  19:43
Cantor Fitzgerald Adjusts Price Target on Merck to $155 From $145
Abbvie : Bernstein Raises Target Price to $275 from $230
THOMSON REUTERS  ·  19:00
Abbvie : Bernstein Raises Target Price to $275 from $230
Novartis Heart Drug Failure Leaves Doctors Seeking Evidence for Genetic Cholesterol Target
Reuters  ·  19:00
Novartis Heart Drug Failure Leaves Doctors Seeking Evidence for Genetic Cholesterol Target
BUZZ-US Stocks Weekly: Spooky
Reuters  ·  19:00
BUZZ-US Stocks Weekly: Spooky
Berenberg Adjusts Price Target on Eli Lilly and Company to $1,570 From $1,400
MT Newswires Live  ·  18:38
Berenberg Adjusts Price Target on Eli Lilly and Company to $1,570 From $1,400
Abbvie : Morgan Stanley Raises Target Price to $346 from $310
THOMSON REUTERS  ·  17:04
Abbvie : Morgan Stanley Raises Target Price to $346 from $310
Novartis Investors Might be Overlooking Risks
Dow Jones  ·  16:53
Novartis Investors Might be Overlooking Risks
Delhi High Court Restrains NPPA Action Against AstraZeneca
TIPRANKS  ·  14:34
Delhi High Court Restrains NPPA Action Against AstraZeneca
SKAN Reports Update on Federal Insider Investigation
TIPRANKS  ·  14:29
SKAN Reports Update on Federal Insider Investigation
Eli Lilly : Berenberg Raises Target Price to $1570 from $1400
THOMSON REUTERS  ·  13:59
Eli Lilly : Berenberg Raises Target Price to $1570 from $1400
Abbvie : Leerink Partners Raises Target Price to $325 from $279
THOMSON REUTERS  ·  11:45
Abbvie : Leerink Partners Raises Target Price to $325 from $279
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Agios Pharma (AGIO)
TIPRANKS  ·  09:40
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Agios Pharma (AGIO)
Analysts Conflicted on These Healthcare Names: AbbVie (ABBV), Regeneron (REGN) and Stoke Therapeutics (STOK)
TIPRANKS  ·  09:30
Analysts Conflicted on These Healthcare Names: AbbVie (ABBV), Regeneron (REGN) and Stoke Therapeutics (STOK)
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Thermo Fisher (TMO) and AbbVie (ABBV)
TIPRANKS  ·  09:20
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Thermo Fisher (TMO) and AbbVie (ABBV)
Merck & Co. Earnings Call Signals Pipeline-Powered Growth
TIPRANKS  ·  10-31 08:18
Merck & Co. Earnings Call Signals Pipeline-Powered Growth

Introduction

Company Name.
VanEck Pharmaceutical ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Issue price:
--